Genmab A/S (NASDAQ:GMAB) Q4 2022 Earnings Call Transcript
Operator: Hello, and welcome to the Genmab Full-year 2022 Conference Call. As a reminder, this conference call is being recorded.
Genmab A/S (GMAB)
Market is closed
News
- First
- << Previous
- 21 - 30
- Next >>
13 High Growth Pharma Stocks that are Profitable
One industry that has rapidly evolved with time and impacted millions, if not billions, of lives is the pharmaceutical sector.
Artisan Mid Cap Fund Exited Its Position in Genmab A/S (GMAB) For Better Opportunities
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
25 Biggest Nordic Companies
The Nordic countries refer to the nation states of Norway, Sweden, Finland, Denmark, and Iceland which are located in Northern Europe.
10 Biotech Stocks With The Biggest Upside
In this article, we discuss the 10 biotech stocks with the biggest upside.
10 Best Immunology Stocks to Invest In
Immunology is the study of the immune system of higher organisms in relation to disease.
15 Biggest European Pharmaceutical Companies
Alongside the United States, Europe has some of the most advanced industries and economies in the world.
5 Most Valuable Danish Companies in the World
In this article, we discuss 5 of the most valuable Danish companies in the world.
Analysts Are Downgrading These 10 Stocks
The post-pandemic economic recovery has hit roadblocks in the past few days as new unemployment data pours in, major Wall Street indexes register small dips, and Chinese authorities extend a regulatory...
Here's Why Artisan Partners Remains Optimistic in Genmab A/S (GMAB)
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ second quarter 2021 investor letter – a copy of which can be downloaded here.
- First
- << Previous
- 21 - 30
- Next >>
Billionaire Hedge Funds
